The role of nimodipine and magnesium sulfate in the prevention and treatment of vascular spasm in patients in the acute rupture of cerebral aneurysms

Cover Page

Cite item

Full Text

Abstract

Vascular spasm in patients with hemorrhage from rupture of cerebral aneurysms is the main cause of adverse outcomes of the disease. One way to treat persistent contraction of cerebral arteries is to use nimodipine and magnesium sulfate. This literature review presents studies on the use of nimodipine and magnesium sulfate in the treatment of vascular spasm, and highlights the main links of pathogenesis and drug action mechanisms.

About the authors

Aleksandr A. Kalinkin

Federal Scientific and Clinical Center of Specialized Types of Medical Care and Medical Technologies of the Federal Medical and Biological Agency of Russia

Author for correspondence.
Email: aleksandr_kalinkin27@mail.ru
ORCID iD: 0000-0002-1605-9088

к.м.н., врач-нейрохирург

Russian Federation, Moscow

A. G. Vinokurov

Federal Scientific and Clinical Center of Specialized Types of Medical Care and Medical Technologies of the Federal Medical and Biological Agency of Russia

Email: avinok@yandex.ru

к.м.н., врач-нейрохирург, врач высшей категории, зав. нейрохирургическим отделением

Russian Federation, Moscow

O. N. Kalinkina

Moscow State University of Medicine and Dentistry a.n. A.I. Evdokimov

Email: aleksandr_kalinkin27@mail.ru
ORCID iD: 0000-0001-5538-904X

врач челюстно-лицевой хирург отделения реконструктивной и пластической хирургии

Russian Federation, Moscow

G. М. Yusubalieva

Federal Scientific and Clinical Center of Specialized Types of Medical Care and Medical Technologies of the Federal Medical and Biological Agency of Russia

Email: aleksandr_kalinkin27@mail.ru
Russian Federation, Moscow

S. M. Chupalenkov

Pirogov Russian National Research Medical University

Email: avinok@yandex.ru
ORCID iD: 0000-0001-5994-3124

студент 6-го курса

Russian Federation, Moscow

References

  1. Крылов В.В., Природов А.В. Факторы риска хирургического лечения аневризм средней мозговой артерии в остром периоде кровоизлияния // Нейрохирургия. — 2011. — №1. — С. 31–41. [Krylov VV, Prirodov AV. Risk factors for surgical treatment of middle cerebral artery aneurysms in the acute period of hemorrhage. Neurosurgery. 2011;(1):31–41. (In Russ).]
  2. Крылов В.В., Природов А.В., Архипов И.В., и др. Моделирование гемодинамических изменений в артериях и артериальных аневризмах головного мозга при сосудистом спазме // Нейрохирургия. — 2013. — №4. — С. 16–25. [Krylov VV, Prirodov AV, Arkhipov IV, et al. The modeling of hemodynamic changes in cerebral arteries and cerebral aneurysms under condition of cerebral angiospasm. Neurosurgery. 2013;(4):16–25. (In Russ).]
  3. Крылов В.В., Природов А.В., Петриков С.С. Нетравматическое субарахноидальное кровоизлияние: диагностика и лечение // Consilium Medicum. Неврология. — 2008. — №1. — С. 14–18. [Krylov VV, Prirodov AV, Petrikov SS. Non-traumatic subarachnoid hemorrhage: diagnosis and treatment. Consilium Medicum. Neurology. 2008;(1):14–18. (In Russ).]
  4. Крылов В.В. Хирургия аневризм головного мозга. Т. I / Под ред. В.В. Крылова. — М.: Медицина, 2011. — С. 156–345. [Krylov VV. Khirurgiya anevrizm golovnogo mozga. Vol. I. Ed by V.V. Krylov. Moscow: Meditsina; 2011. Рр. 156–345. (In Russ).]
  5. Мельникова Е.А., Крылов В.В. Нейропсихологические исходы после раннего хирургического лечения аневризм сосудов // Нейрохирургия. — 2008. — №4. — С. 21–29. [Melnikova EA, Krylov VV. Neuropsychological outcomes after early surgical treatment of cerebral vessels. Neurosurgery. 2008;(4):21–29. (In Russ).]
  6. Калинкин А.А., Крылов В.В., Петриков С.С., и др. Влияние терапии антагонистами кальция на исходы лечения больных с разрывом церебральных аневризм и высоким риском развития сосудистого спазма // Неврологический журнал. — 2016. — №5. — С. 12–18. [Kalinkin AA, Krylov VV, Petrikov SS, et al. Effect of calcium antagonist therapy on outcomes of treatment of patients with rupture of cerebral aneurysms and a high risk of developing vascular spasm. Neurological journal. 2016;(5):12–18. (In Russ).]
  7. Калинкин А.А., Петриков С.С., Хамидова Л.Т., Крылов В.В. Прогностическая значимость концентрации лейкоцитов в венозной крови в остром периоде разрыва церебральных аневризм // Журнал неврологии и психиатрии им. С.С. Корсакова. — 2017. — №7. — С. 4–9. [Kalinkin AA, Petrikov SS, Khamidova LT, Krylov VV. The prognostic significance of the concentration of leukocytes in venous blood in the acute period of rupture of cerebral aneurysms. Journal of Neurology and Psychiatry. S.S. Korsakova. 2017;(7):4–9. (In Russ).]
  8. Aaslid R, Markwalder TM, Nornes H. Noninvasive transcranial Doppler ultrasound, recording of flow velocity in basal cerebral arteries. J Neurosurg. 1982;57:769–774. doi: 10.3171/jns.1982.57.6.0769.
  9. Петриков С.С., Крылов В.В. Нейромониторинг у больных с внутричерепными кровоизлияниями. Часть 1. Мониторинг внутричерепного давления, церебральной оксигенации и метаболизма // Нейрохирургия. — 2009. — № 4. — С. 10–18. [Petrikov SS, Krylov VV. Neuromonitoring in patients with intracranial hemorrhage. Part 1. Monitoring of intracranial pressure, cerebral oxygenation and metabolism. Neurosurgery. 2009;(4):10–18. (In Russ).]
  10. Петриков С.С., Крылов В.В. Нейромониторинг у больных с внутричерепными кровоизлияниями. Часть 2. Оценка мозгового кровотока и нейрофизиологический мониторинг // Нейрохирургия. — 2010. –№1. — С. 5–9. [Petrikov SS, Krylov VV. Neuromonitoring in patients with intracranial hemorrhage. Part 2. Assessment of cerebral blood flow and neurophysiological monitoring. Neurosurgery. 2010;(1):5–9. (In Russ).]
  11. Зефиров А.Л., Ситдикова Г.Ф. Ионные каналы нервного окончания // Успехи физиологических наук. — 2002. — T.33. — №4. — С. 3–33. [Zefirov AL, Sitdikova GF. Ionic channels of the nerve ending. Uspekhi fiziologicheskikh nauk. 2002;33(4):3–33. (In Russ).]
  12. Зефиров А.Л., Ситдикова Г.Ф. Ионные каналы возбудимой клетки (структура, функция, патология). — Казань: Арт-кафе, 2010. — С. 164–201. [Zefirov AL, Sitdikova GF. Ionnye kanaly vozbudimoy kletki (struktura, funktsiya, patologiya). Kazan’: Art Cafe; 2010. Pp. 164–201. (In Russ).]
  13. Dreier JP. The role of spreading depression, spreading depolarization and spreading ischemia in neurological disease. Nat Med. 2011;17:439–447. doi: 10.1038/nm.2333.
  14. Schubert GA, Seiz M, Hegewald AA, et al. Hypoperfusion in the acute phase of subarachnoid hemorrhage. Early brain injury or cerebral vasospasm. Pathophysiology. 2011;(1):35–38. doi: 10.1007/978-3-7091-0353-1_6.
  15. Крылов В.В., Гусев С.А., Титова Г.П., Гусев А.С. Сосудистый спазм при субарахноидальном кровоизлиянии: клинический атлас. —М.: Макцентр, 2000. — С. 45–82. [Krylov VV, Gusev SA, Titova GP, Gusev AS. Vascular spasm in case of subarachnoid hemorrhage: a clinical atlas. Moscow: Maktsentr; 2000. Рр. 45–82. (In Russ).]
  16. Rizzuto R. Microdomains of intracellular Ca2+: molecular determinants and functional consequences. Physiol Rev. 2006;86:369–408. doi: 10.1152/physrev.00004.2005.
  17. Alen GS, Ahn HS, Preziosi TJ. Cerebral arterial spasm — a controlled trial of nimodipine in patients with subarachnoid hemorrhage. N Engl J Med. 1983;308:619–624. doi: 10.1056/NEJM198303173081103.
  18. Jan M, Buchheit F, Tremoulet M. Therapeutic trial of intravenous nimodipine in patients with established cerebral vasospasm after rupture of intracranial aneurysms. Neurosurgery.1988;23(2):154–157. doi: 10.1227/00006123-198808000-00004.
  19. Badjatia N, Topcuoglu MA, Pryor JC, Rabinov JD. Preliminary experience with intra-arterial nicardipine as a treatment for cerebral vasospasm. Am J Neuroradiol. 2004;25:819–826. doi: 10.3171/JNS/2008/108/3/0458.
  20. Toyota BD. The effectiveness of short course of nimodipine in patients with a good grade aneurysmal subarachnoid hemorrhage. J Neurosurg. 1999;90(2):203–206. doi: 10.3171/jns.1999.90.2.0203.
  21. Feigin VL, Rinkel GJ, Algra A, et al. Calcium antagonists in patients with subarachnoid hemorrhage, aneurysm. A systematic review. Neurology. 1998;50:876–883. doi: 10.1212/wnl.50.4.876.
  22. Connolly ES, Rabinstein AA, Carhuapoma JR, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2012;43:1711–1737. doi: 10.1161/STR.0b013e3182587839.
  23. Ohman J, Servo A, Heiskanen O. Long-term effects of nimodipine on cerebral infarcts and outcome after aneurysmal subarachnoid hemorrhage and surgery. J Neurosurg. 1991;74(1):8–13. doi: 10.3171/jns.1991.74.1.0008.
  24. Rinkel GJ, Feigin VL, Algra A, et al. Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev. 2002;(4):CD000277. doi: 10.1002/14651858.CD000277.pub3.
  25. Soppi V, Kokki H, Koivisto T, et al. Early-phase pharmacokinetics of enteral and parenteral nimodipine in patients with acute subarachnoid haemorrhage — a pilot study. Eur J Clin Pharmacol. 2007;63(4):355–361. doi: 10.1007/s00228-007-0267-7.
  26. Soppi V, Karamanakos PN, Koivisto T, et al. Randomized outcome study of enteral versus intravenous nimodipine in 171 patients after acute aneurysmal subarachnoid hemorrhage. World Neurosurg. 2012;78:101–109. doi: 10.1016/j.wneu.2011.09.030.
  27. Kronvall E, Undron P, Romner B, et al. Nimodipine in aneurysmal subarachnoid hemorrhage: a randomized study of intravenous or peroral administration. J Neurosurg. 2009;110(1):58–63. doi: 10.3171/2008.7.JNS08178.
  28. Musahl C, Henkes H, Vajda Z, et al. Continuous local intra-arterial nimodipine administration in severe symptomatic vasospasm after subarachnoid hemorrhage. Neurosurgery. 2011;68(6):1541–1547. doi: 10.1227/NEU.0b013e31820edd46.
  29. Cho WS, Kang HS, Kim JE, et al. Within the arterial nimodipine infusion in patients with cerebral vasospasm aneurysmal subarachnoid hemorrhage. Intervals Neuroradiol. 2011;17(2):169–178. doi: 10.1177/159101991101700205.
  30. Dehdashti AR, Binaghi S, Uske A, Regli L. Intraarterial nimodipine for the treatment of symptomatic vasospasm after aneurysmal subarachnoid hemorrhage: a preliminary study. Neurol India. 2011;59(6):810–816. doi: 10.4103/0028-3886.91356.
  31. Keyrouz SG, Diringer MN. Clinical review: prevention and therapy of vasospasm in subarachnoid hemorrhage. Crit Care. 2007;11(4):220. doi: 10.1186/cc5958.
  32. Stiefel MF, Heuer GG, Abrahams JM, et al. The effect of nimodipine on cerebral oxygenation in patients with low class subarachnoid hemorrhage. J Neurosurg. 2004;101(4):594–599. doi: 10.3171/jns.2004.101.2.0241.
  33. Choi HA, Ko SB, Chen H, et al. Acute effects of nimodipine on cerebral vasculature and brain metabolism in high grade subarachnoid hemorrhage patients. Neurocrit Care. 2012;16(3):363–367. doi: 10.1007/s12028-012-9670-8.
  34. Velat GJ, Kimball MM, Mocco JD, Ho BL. Vasospasm after aneurysmal subarachnoid hemorrhage: a review of randomized controlled trials and meta-analysis in the literature. World Neurosurg. 2011;76(5):446–454. doi: 10.1016/j.wneu.2011.02.030.
  35. Dorrance D, Lowe D, Neil-Dwyer G. Controlled trial of nimodipine in aneurysm patients early after subarachnoid hemorrhage. Neurosurgery. 1988;22(3):484–491. doi: 10.1136/bmj.298.6674.636.
  36. Haley EC, Kassell NF, Apperson-Hansen C, et al. A randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in North America. J Neurosurg. 1997;86:467–474. doi: 10.3171/jns.1997.86.3.0467.
  37. Dalbasti T, Karabiyikoglu M, Ozdamar N, et al. Efficacy of controlled-release papaverine pellets in preventing symptomatic cerebral vasospasm. J Neurosurg. 2001;95:44–50. doi: 10.3171/jns.2001.95.1.0044.
  38. Van den Bergh WM, Albrecht KW, Berkelbach van der Sprenkel JW, Rinkel GJ. Magnesium therapy after aneurysmal subarachnoid haemorrhage a dose-finding study for long term treatment. Acta Neurochir. 2003;145:195–199. doi: 10.1007/s00701-002-1064-9.
  39. Üstün ME, Duman A, Ögün CÖ. Effects of nimodipine and magnesium sulfate on endogenous antioxidant levels in brain tissue after experimental head trauma. J Neurosurgi Anesthesiol. 2001;13(3): 227–232. doi: 10.1097/00008506-200107000-00008.
  40. Chen T, Carter BS. Role of magnesium sulfate in aneurysmal subarachnoid hemorrhage management: a meta-analysis of controlled clinical trials. Asian J Neurosurg. 2011;6(1):26–31. doi: 10.4103/1793-5482.85632.
  41. Stippler M, Crago E, Levy E, et al. Magnesium infusion for the prevention of vasospasm after subarachnoid hemorrhage. J Neurosurg. 2006;105:723–729. doi: 10.3171/jns.2006.105.5.723.
  42. Van den Bergh WM, Dijkulzen RM, Rinkel GJ. Potentials of magnesium treatment in subarachnoid hemorrhage. Magnes Res. 2004;17(4):301–313. doi: 10.4103/1793-5482.85632.
  43. Boet R, Mee E. Magnesium sulfate in the management of patients with Fisher grade 3 subarachnoid hemorrhage: a pilot study. Neurosurgery. 2000;47:602–606. doi: 10.1097/00006123-200009000-00014.
  44. Chia RY, Hughes RS, Morgan MK. Magnesium: a useful adjunct in the prevention of cerebral vasospasm following aneurysmal subarachnoid haemorrhage. J Clin Neurosci. 2002;9:279–281. doi: 10.1054/jocn.2001.1039.
  45. Нестерова О.С. Оптимизация лечения сосудистого спазма в остром периоде субарахноидального кровоизлияния на основе клинико-инструментального мониторинга: Автореф. дис. … канд. мед. наук. — М., 2007. — 24 с. [Nesterova OS. Optimizatsiya lecheniya sosudistogo spazma v ostrom periode subarakhnoidal’nogo krovoizliyaniya na osnove kliniko-instrumental’nogo monitoringа. [dissertation abstract] Moscow; 2007. 24 р. (In Russ).] Доступно по: https://search.rsl.ru/ru/record/01003052988. Ссылка активна на 15.09.2019.
  46. Yahia AM, Kirmani JF, Qureshi AI. The safety and feasibility of continuous intravenous magnesium sulfate for prevention of cerebral vasospasm in aneurysmal ubarachnoid hemorrhage. Neurocrit Care. 2005;3:16–23. doi: 10.1385/NCC:3:1:016.
  47. Калинкин А.А., Петриков С.С., Крылов В.В. Прогностическая значимость концентрации ионов кальция и магния в плазме крови в развитии сосудистого спазма в остром периоде разрыва церебральных аневризм / Поленовские чтения: материалы XII научно-практической конференции. — М., 2013. — C. 133–134. [Kalinkin AA, Petrikov SS, Krylov VV. Prognosticheskaya znachimost’ kontsentratsii ionov kal’tsiya i magniya v plazme krovi v razvitii sosudistogo spazma v ostrom periode razryva tserebral’nykh anevrizm. (Conference proceeding) Polenovskie chteniya: materialy XII nauchno-prakticheskoy konferentsii. Moscow; 2013. Pp. 133–134. (In Russ).]
  48. Muroi C, Terzic A, Fortunati M, et al. Magnesium sulphate in the management of patients with aneurysmal subarachnoid hemorrhage: a randomized, placebo-controlled, dose-adapted trial. Surg Neurol. 2008;69:33–39. doi: 10.1016/j.surneu.2007.07.07.015.
  49. Friedlich D, Agner C, Boulos AS, et al. Retrospective analysis of parenteral magnesium sulfate administration in decreased incidence of clinical and neuroradiological cerebral vasospasm: a single center experience. Neurol Res. 2009;31(6):621–625. doi: 10.1179/174313209X38232.
  50. Van den Bergh WM, Algra A, van Kooten F, et al. Magnesium sulfate in aneurysmal subarachnoid hemorrhage: a randomized controlled trial. Stroke. 2005;36:1011–1015. doi: 10.1161/01.STR.0000160801.96998.57.
  51. Westermaier T, Stetter C, Vince GH, et al. Prophylactic intravenous magnesium sulfate for treatment of aneurysmal subarachnoid hemorrhage: a randomized placebo-controlled, clinical study. Crit Care Med. 2010;38:1284–1290. doi: 10.1097/CCM.0b013e3181d9da1e.
  52. Muir KW, Lees KR, Ford I, Davis S. Magnesium for acute stroke intravenous magnesium efficacy in stroke trial: randomised controlled trial. Lancet. 2004;363:439–445. doi: 10.1016/S0140-6736(04)15490-1.
  53. Veyna RS, Seyfried D, Burke DG, et al. Magnesium sulfate therapy after aneurysmal subarachnoid hemorrhage. J Neurosurg. 2002;96:510–514. doi: 10.3171/jns.2002.96.3.0510.
  54. Wong GK, Chan MT, Boet R, et al. Intravenous magnesium sulfate after aneurysmal subarachnoid hemorrhage: a prospective randomized pilot study. J Neurosurg Anesthesiol. 2006;18:142–148. doi: 10.1097/00008506-200604000-00009.
  55. Wong GK, Kwok R, Tang K, et al. Effects of magnesium sulfate infusion on cerebral perfusion in patients after aneurysmal SAH. Acta neurochirurgica. Supplement 2010;106:133–135. doi: 10.1097/00008506-200604000-00009.
  56. Dorhout Mees SM, Algra A, Vandertop WP, et al. Magnesium for aneurysmal subarachnoid haemorrhage (MASH-2): a randomised placebo-controlled trial. Lancet. 2012;380(9836):44–49. doi: 10.1016/S0140-6736(12)60724-7.
  57. Ma L, Liu WG, Zhang JM, et al. Magnesium sulfate in the treatment of patients with aneurysms of subarachnoid hemorrhage: a meta-analysis of prospective controlled trials. Brain Injection. 2010;24(5):730–735. doi: 10.3109/02699051003610516.
  58. Wong GK, Boet R, Poon WS, et al. Intravenous magnesium sulphate for aneurysmal subarachnoid hemorrhage: an updated systemic review and meta-analysis. Crit Care. 2011;15:52. doi: 10.1186/cc10017.
  59. Odom MJ, Zuckerman SL, Mocco J. the role of magnesium in the management of cerebral vasospasm. Neurol Res Int. 2013;2013:943914. doi: 10.1155/2013/943914.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Scheme of the pathogenesis of vascular spasm and cerebral ischemia after rupture of arterial aneurysms of the brain

Download (277KB)
Indexing metadata
3. Fig. 2. Scheme of the effect of magnesium ions on the pathogenesis of vascular spasm and ischemia in case of subarachnoid hemorrhage

Download (171KB)
Indexing metadata

Copyright (c) 2020 Kalinkin A.A., Vinokurov A.G., Kalinkina O.N., Yusubalieva G.М., Chupalenkov S.M.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies